[426 Pages Report] The global demand for drug formulation is expected to increase at 5.6% CAGR over the forecast period from 2022 to 2032. The sales of the drug formulations market are estimated to reach a valuation of US$ 1.58 Trillion by 2022. According to the study, oral formulations projects to grow exponentially with a CAGR of 6.0% during the forecast period.
Market Outlook:
Data Points
Market Insights
Drug Formulation Market Value 2021
US$ 1.50 Trillion
Drug Formulation Market Value 2022
US$ 1.58 Trillion
Drug Formulation Market Value 2032
US$ 2.87 Trillion
Drug Formulation Market CAGR 2022 to 2032
5.6%
Market Share of Top 5 Countries
68.4%
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Sales Analysis of Drug Formulation Market from 2012 to 2021 Vs Demand Outlook for 2022 to 2032
According to Future Market Insights (FMI), the overall sales of drug formulation grew at a CAGR of 5.1% between 2012 and 2021. However, the demand in the drug formulation market is expected to increase at a CAGR of 5.6%, surpassing US$ 2.87 Trillion by the end of 2032.
The pharmaceutical industry has experienced a substantial revolution with the introduction of novel technologies as well as more affordable and cost-effective manufacturing methods. Robotics and artificial intelligence are increasingly being used in the pharmaceutical industry to decrease production waste and downtime on the factory floor. Personalized medicine's continual breakthroughs have also made it feasible to establish patient-centric models by opening up several chances to address a wide range of medical conditions.
In addition, the growing prevalence of the chronic disease among the population, and rising investment flow in this sector are positively driving the market growth. The consumption of pharmaceuticals is also being influenced by the growing world population, which has helped the drug formulation industry rise recently. As a result, the use of antidepressants doubled, consumption of antihypertensive and antidiabetic medications almost doubled, and consumption of cholesterol-lowering medications nearly quadrupled between 2000 and 2015 in Organization for Economic Cooperation and Development (OECD) nations. Increasing the focus on non-communicable diseases (NCDs), such as diabetes and hypertension, which are already widespread in developed nations, while communicable diseases, such as Acquired immunodeficiency syndrome (AIDS), malaria, and tuberculosis, which affect many developing economies, continue to exist.
The global drug formulation market is expected to be valued at US$ 2.87 Trillion by the end of 2032, registering a CAGR of 5.6% in the forecast period.
What are the Key Opportunities for Drug Formulation Manufacturers?
Until the 20th century, there were relatively limited medicines and treatment options available for chronic diseases like cancer or other rare diseases which indeed projected limited treatment options. However, the growth in research efforts and investment for drug development has projected a positive impact projecting an opportunistic factor for the manufacturers for new drug development in the market. The opportunities are growing because of the increasing advances in molecular biology to develop new agents.
The amount of revenue that pharmaceutical companies anticipate gaining from a new drug, the estimated cost of developing that drug, and laws that affect the supply and demand for drugs also play a role in the amounts of money they invest in research and development (Research and Development). For instance, according to Federal Government Statistics, pharmaceutical businesses invested an average of about 25% of their revenue in Research and Development. In 2019, Top Research and Development spenders 2021 spent close to one-fifth of their income on Research and Development. The pharmaceutical industry is undoubtedly a global one, although US-based businesses often spend the most on Research and Development. Such conditions are anticipated to create lucrative opportunities for local players to reinforce their position and increase their market share over the forecast period.
Find your sweet spots for generating winning opportunities in this market.
What are the Factors Restraining Demand for Drug Formulation?
Currently, trial and error procedures are used to generate pharmaceutical compositions. This process is a time-consuming method that takes a long time to complete, involving high expenses, and a significant amount of work labors to build and maintain. However, complexity in compliance with the regulatory values would impact the drug development process, if the formulation is unable to comply with the regulatory requirement the repeat process for drug development would negatively impact the pharmaceutical industry economy to a high extent. The pharmaceutical sector is under pressure to lower healthcare costs and the production of new active pharmaceutical ingredients (APIs). Thus this factor expects to restrain the pharmaceutical industries to involve in the drug development process which in turn expects to hamper the market growth.
Additionally, complexity in the supply chain exists to be a restricting factor expected to hamper the drug formulation market growth. Most pharmaceutical companies have a complex supply chain, which is either inefficient or under-utilized. The complexity of the supply chain is due to low flexibility or its cost-effective nature. However, increasing generic competition has dented the profitability of big players and the trend expects to continue over the years. Many pharmaceutical companies have started to reorganize their supply chain in response to changing market structures, but these changes are only meant to address short-term challenges. Along with patent cliffs, the shortening of effective patent life is the major issue in the drug formulation market due to increasing time-to-market and stringent regulations.
Country-wise Insights
Why is the US Considered to be the Largest Market for Drug formulations?
According to Future Market Insights, the US witnessed dominance in the North American drug formulation market, accounting for the highest total market share of 91.3% in 2021, and is projected to continue to exhibit high growth through 2022 & beyond.
The worldwide pharmaceutical market is significantly supported by the US market. Growing Research and Development spending has sped up FDA approvals, which are expected to remain stable until 2021. In 2021, the government approved 50 innovative medications, which was broadly in pace with the approval of 53 drugs the year before.
According to FMI Analysis, US pharmaceutical production and sales are expected to continue strong due to the ongoing global vaccination campaign and the accumulated demand for both necessary and optional medical treatments in 2022.
Why is Germany Considered a Lucrative Market for Drug formulation in Europe?
Germany is set to exhibit growth at a CAGR of around 5.2% in the Europe drug formulation market during the forecast period. The German healthcare industry is heavily controlled, and pharmaceutical companies do not face a lot of legal pressure to cut their drug sales prices for final consumers exploring opportunities for new entrance and positive opportunities for the existing manufacturers to invest and develop products in the market. Additionally, the presence of major players like Boehringer Ingelheim International Gmbh, Bayer AG, Merck KGa, Fresenius Kabi, and many more expect to augment the production capacity and make high product availability in the market witnessing the country’s dominance in the Europe market.
What will be the Demand Outlook for the Drug formulation Market in China?
China is projected to expand at a CAGR rate of 7.3% and is anticipated to account the half of the East Asia drug formulation marker revenue valued to reach around US$ 320.7 Billion in 2032.
The pharmaceutical industry in China is also very fragmented; most producers are small and medium-sized businesses. As a result, Research and Development investment is modest in comparison to international competitors. By 2025, the 14th Five-Year Plan wants to raise spending to 10% of sales. Pharmaceutical multinational companies (MNCs) with large market positions include AstraZeneca, Novartis, and Novo Nordisk, each of which held between 8 and 10% of the domestic market share in 2019. Since distribution networks are so important to the industry, domestic pharmaceutical companies like Sinopharm and Shanghai Pharmaceuticals have a firm grip on them. The government has been attempting to consolidate the pharmaceutical business and raise the average size of firms as a result of the industry's fragmentation to assist in quality inspection and improvement.
Major medical reforms have also been implemented in order to advance the development and maturity of China's pharmaceutical industry, in addition to the aforementioned policy changes.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-wise Insights
Which Type of Dosage Form is Expected to be Most Preferred in Drug Formulation Market?
The oral formulation contribute about 42.2% of the market share in 2021 and is expected to register a CAGR of 6.0% in the forecast period. Oral formulations are highly preferred over other dosage forms owing to their advantageous factors, including patient compliance, non-invasiveness, and ease of drug administration.
Which is the Leading Indication in Drug Formulation Market?
Central Nervous System Disorders are expected to hold more than a 14% market share, exhibiting growth at 3.1% CAGR in the forecast period.
The growing prevalence of central nervous system disorders among the growing population has surged the demand for novel drugs in the market intending to explore opportunities in the market. For instance, the development of novel biologic drugs, such as recombinant proteins or gene therapies, is essential for the treatment of Alzheimer's disease (AD) and the therapy of the aging brain.
How did the big pharma companies influence the drug formulation market growth?
Based on end user, the big pharma companies held the highest market share of 39.9% in 2021 and is poised to expand at a CAGR of 5.1% over the upcoming decade. Big pharma companies with well-structured research and development sector along with high investment in product development and innovation has accelerated the production capacity of novel drug formulations.
Competitive Landscape
Key manufacturers are implementing strategies in the drug formulation market, including mergers and acquisitions and advanced product launches by acquiring approvals. To acquire a competitive edge in the market, the key companies are focusing on collaborating with the research institutes.
A definitive merger agreement between Bristol Myers Squibb and Turning Point Therapeutics was signed on June 20, 2022. This acquisition will expand BMS's selection of oncology drugs because Turning Point Therapeutics is a precision oncology company that is still in the clinical development stage.
AstraZeneca introduced The Evusheld long-acting antibody combo to the public on March 20, 2022. For the pre-exposure prophylaxis (prevention) of COVID-19 in a sizable population, it has received authorization in Europe.
Report Scope
Attribute
Details
Forecast Period
2022 to 2032
Historical Data Available for
2012 to 2021
Market Analysis
US$ Billion for Value
Key Regions Covered
North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa
Key Countries Covered
US, Canada, Brazil, Mexico, Argentina, UK, Germany, France, Italy, Spain, Russia, BENELUX, China, Japan, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, North Africa, GCC Countries, Turkey, Egypt, and South Africa
Key Market Segments Covered
Dosage form, Indication, End User, and Region
Key Companies Profiled
AstraZeneca plc.
Bristol-Myers Squibb
Eli Lilly and Company
Gilead Sciences, Inc.
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
AbbVie Inc.
Boehringer Ingelheim International GmbH
F. Hoffmann-La Roche AG
Johnson & Johnson
3M Company
Bayer AG
Teva Pharmaceuticals Industries Ltd.
Amgen, Inc.
Sanofi SA
GlaxoSmithKline plc
Boston Scientific Corporation
Gerresheimer AG
Nimbus Therapeutics
Antares Pharma, Inc.
IDEAYA Biosciences, Inc.
Pricing
Available upon Request
Key Market Segments Covered in Drug Formulation Industry Research
By Dosage Form:
Oral formulations
Tablets
Immediate Release
Modified Release
Chewable
Effervescent
Capsules
Hard Gelatin Capsules
Softgel Capsules
Others
Powders & Granules
Lozenges & Pastilles
Gummies
Others
Parenteral formulations
Solutions
Suspensions
Emulsions for injection or infusion
Powders for injection or infusion
Gels for injection implants
Topical formulations
Pastes
Ointments and oils
Creams, lotions, and foams.
Gels, tinctures, and powders
Sprays and patches
Inhalation formulations
Pressurized Metered Dose Inhaler
Dry Powder Inhaler (DPI)
Nebulizer
By Indication:
Infectious Diseases
Cancer
Cardiovascular Diseases
Diabetes
Respiratory Diseases
Central Nervous System Disorders
Autoimmune Diseases
Gastrointestinal Diseases
Musculoskeletal Disorders
Dermatological Disorders
Other
By End User:
Big pharma
Small & Medium Size Pharma
Biotech Companies
By Region:
North America
Latin America
Europe
South Asia
East Asia
Oceania
The Middle East and Africa (MEA)
Frequently Asked Questions
The global drug formulation market is expected to be worth US$ 1.50 Tn in 2021 and is set to expand by 1.8x over the next eleven years.
The drug formulation market is expected to reach US$ 2.87 Bn by end of 2032, exhibiting growth at a CAGR of 5.6% between 2022 and 2032.
Key trends influencing the sales in the drug formulation market include a focus on production capacity expansion by implementing an outsourcing strategy, an approach towards advanced manufacturing techniques, expanding product sales through the online platform, and adopting strategic alliances are the emerging trends adopted by the key players.
North America is expected to lead the global market, with the U.S. contributing over 91.3% of the revenue share to the regional market in 2022.
The U.S., China, Japan, Germany, and Canada are the top five countries, which are expected to drive demand in the drug formulation market.
Table of Content
1. Executive Summary | Drug Formulation Market
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply-Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusion and Exclusion
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Key Inclusion
4.1. Product Adoption / Consumption Analysis
4.2. Key Promotional Strategies, By Manufacturers
4.3. Disease Epidemiology
4.4. Pipeline Assessment
4.5. Regulatory Landscape
4.6. Reimbursement Outlook
4.7. PESTLE Analysis
4.8. Porter’s Analysis
4.9. Supply Chain Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Industry Market Outlook
5.1.3. Pharmaceutical Industry Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Rise In Incidence of chronic disease
5.2.2. Growth In Production Capacity
5.2.3. Increase In Adoption Rate
5.2.4. Increasing Economic Affluence In Emerging Economies
5.2.5. Distribution Channel
5.2.6. Cost Consideration
5.2.7. Regulatory Scenario
5.2.8. Growing Geriatric Population
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. Current COVID-19 Statistics and Probable Future Impact
6.2. COVID-19 and Impact Analysis
6.2.1. Revenue By Dosage Form
6.2.2. Revenue By Indication
6.2.3. Revenue By End User
6.2.4. Revenue By Country
7. Global Drug Formulation Market Demand (in Value US$ Million) Analysis 2012 to 2021 and Forecast, 2022 to 2032
7.1. Historical Market Value (US$ Million) Analysis, 2012 to 2021
7.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Drug Formulation Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Million) Analysis By Dosage Form, 2012 to 2021
8.3. Current and Future Market Size (US$ Million) Analysis By Dosage Form, 2022 to 2032
8.3.1. Oral formulations
8.3.1.1. Tablets
8.3.1.1.1. Immediate Release
8.3.1.1.2. Modified Release
8.3.1.1.3. Chewable
8.3.1.1.4. Effervescent
8.3.1.2. Capsules
8.3.1.2.1. Hard Gelatin Capsules
8.3.1.2.2. Softgel Capsules
8.3.1.3. Powders & Granules
8.3.1.4. Lozenges & Pastilles
8.3.1.5. Gummies
8.3.1.6. Others
8.3.2. Parenteral formulations
8.3.2.1. Solutions
8.3.2.2. Suspensions
8.3.2.3. Emulsions for injection or infusion
8.3.2.4. Powders for injection or infusion
8.3.2.5. Gels for injection implants
8.3.3. Topical formulations
8.3.3.1. Pastes
8.3.3.2. Ointments and oils
8.3.3.3. Creams, lotions, and foams.
8.3.3.4. Gels, tinctures, and powders.
8.3.3.5. Sprays and patches.
8.3.4. Inhalation formulations
8.3.4.1. Pressurized Metered Dose Inhaler
8.3.4.2. Dry Powder Inhaler (DPI)
8.3.4.3. Nebulizer
8.4. Market Attractiveness Analysis By Dosage Form
9. Global Drug Formulation Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Indication
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) Analysis By Indication, 2012 to 2021
9.3. Current and Future Market Size (US$ Million) Analysis Forecast By Indication, 2022 to 2032
9.3.1. Infectious Diseases
9.3.2. Cancer
9.3.3. Cardiovascular Diseases
9.3.4. Diabetes
9.3.5. Respiratory Diseases
9.3.6. Central Nervous System Disorders
9.3.7. Autoimmune Diseases
9.3.8. Gastrointestinal Disease
9.3.9. Musculoskeletal disorders
9.3.10. Dermatology disorders
9.3.11. Others
9.4. Market Attractiveness Analysis By Indication
10. Global Drug Formulation Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) Analysis By End User, 2012 to 2021
10.3. Current and Future Market Size (US$ Million) Analysis Forecast By End User, 2022 to 2032
10.3.1. Big pharma
10.3.2. Small & Medium Size Pharma- Companies
10.3.3. Biotech Companies
10.4. Market Attractiveness Analysis By End User
11. Global Drug Formulation Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Region
11.1. Introduction
11.2. Historical Market Size (US$ Million) Analysis By Region, 2012 to 2021
11.3. Current and Future Market Size (US$ Million) Analysis Forecast By Region, 2022 to 2032
11.3.1. North America
11.3.2. Latin America
11.3.3. Europe
11.3.4. South Asia
11.3.5. East Asia
11.3.6. Oceania
11.3.7. Middle East & Africa (MEA)
11.4. Market Attractiveness Analysis By Region
12. North America Drug Formulation Market Analysis 2012 to 2021 and Forecast 2022 to 2032
12.1. Introduction
12.2. Historical Market Size (US$ Million) By Market Taxonomy, 2012 to 2021
12.3. Current and Future Market Size (US$ Million) By Market Taxonomy, 2022 to 2032
12.3.1. By Country
12.3.1.1. US
12.3.1.2. Canada
12.3.2. By Dosage Form
12.3.3. By Indication
12.3.4. By End User
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Dosage Form
12.4.3. By Indication
12.4.4. By End User
12.5. Key Market Participants - Intensity Mapping
12.6. Country-Level Analysis & Forecast
12.6.1. U.S. Drug Formulation Market
12.6.1.1. Introduction
12.6.1.2. Market Analysis and Forecast By Market Taxonomy
12.6.1.2.1. By Dosage Form
12.6.1.2.2. By Indication
12.6.1.2.3. By End User
12.6.2. Canada Drug Formulation Market
12.6.2.1. Introduction
12.6.2.2. Market Analysis and Forecast By Market Taxonomy
12.6.2.2.1. By Dosage Form
12.6.2.2.2. By Indication
12.6.2.2.3. By End User
13. Latin America Drug Formulation Market Analysis 2012 to 2021 and Forecast 2022 to 2032
13.1. Introduction
13.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021
13.3. Current and Future Market Size (US$ Million) By Market Taxonomy, 2022 to 2032
13.3.1. By Country
13.3.1.1. Brazil
13.3.1.2. Mexico
13.3.1.3. Argentina
13.3.1.4. Rest of Latin America
13.3.2. By Dosage Form
13.3.3. By Indication
13.3.4. By End User
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Dosage Form
13.4.3. By Indication
13.4.4. By End User
13.5. Key Market Participants - Intensity Mapping
13.6. Country-Level Analysis & Forecast
13.6.1. Brazil Drug Formulation Market
13.6.1.1. Introduction
13.6.1.2. Market Analysis and Forecast By Market Taxonomy
13.6.1.2.1. By Dosage Form
13.6.1.2.2. By Indication
13.6.1.2.3. By End User
13.6.2. Mexico Drug Formulation Market
13.6.2.1. Introduction
13.6.2.2. Market Analysis and Forecast By Market Taxonomy
13.6.2.2.1. By Dosage Form
13.6.2.2.2. By Indication
13.6.2.2.3. By End User
13.6.3. Argentina Drug Formulation Market
13.6.3.1. Introduction
13.6.3.2. Market Analysis and Forecast By Market Taxonomy
13.6.3.2.1. By Dosage Form
13.6.3.2.2. By Indication
13.6.3.2.3. By End User
14. Europe Drug Formulation Market Analysis 2012 to 2021 and Forecast 2022 to 2032
14.1. Introduction
14.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021
14.3. Current and Future Market Size (US$ Million) By Market Taxonomy, 2022 to 2032
14.3.1. By Country
14.3.1.1. Germany
14.3.1.2. Italy
14.3.1.3. France
14.3.1.4. The UK
14.3.1.5. Spain
14.3.1.6. BENELUX
14.3.1.7. Russia
14.3.1.8. Rest of Europe
14.3.2. By Dosage Form
14.3.3. By Indication
14.3.4. By End User
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Dosage Form
14.4.3. By Indication
14.4.4. By End User
14.5. Key Market Participants - Intensity Mapping
14.6. Country-Level Analysis & Forecast
14.6.1. Germany Drug Formulation Market
14.6.1.1. Introduction
14.6.1.2. Market Analysis and Forecast By Market Taxonomy
14.6.1.2.1. By Dosage Form
14.6.1.2.2. By Indication
14.6.1.2.3. By End User
14.6.2. Italy Drug Formulation Market
14.6.2.1. Introduction
14.6.2.2. Market Analysis and Forecast By Market Taxonomy
14.6.2.2.1. By Dosage Form
14.6.2.2.2. By Indication
14.6.2.2.3. By End User
14.6.3. France Drug Formulation Market
14.6.3.1. Introduction
14.6.3.2. Market Analysis and Forecast By Market Taxonomy
14.6.3.2.1. By Dosage Form
14.6.3.2.2. By Indication
14.6.3.2.3. By End User
14.6.4. U.K. Drug Formulation Market
14.6.4.1. Introduction
14.6.4.2. Market Analysis and Forecast By Market Taxonomy
14.6.4.2.1. By Dosage Form
14.6.4.2.2. By Indication
14.6.4.2.3. By End User
14.6.5. Spain Drug Formulation Market
14.6.5.1. Introduction
14.6.5.2. Market Analysis and Forecast By Market Taxonomy
14.6.5.2.1. By Dosage Form
14.6.5.2.2. By Indication
14.6.5.2.3. By End User
14.6.6. BENELUX Drug Formulation Market
14.6.6.1. Introduction
14.6.6.2. Market Analysis and Forecast By Market Taxonomy
14.6.6.2.1. By Dosage Form
14.6.6.2.2. By Indication
14.6.6.2.3. By End User
14.6.7. Russia Drug Formulation Market
14.6.7.1. Introduction
14.6.7.2. Market Analysis and Forecast By Market Taxonomy
14.6.7.2.1. By Dosage Form
14.6.7.2.2. By Indication
14.6.7.2.3. By End User
15. South Asia Drug Formulation Market Analysis 2012 to 2021 and Forecast 2022 to 2032
15.1. Introduction
15.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021
15.3. Current and Future Market Size (US$ Million) By Market Taxonomy, 2022 to 2032
15.3.1. By Country
15.3.1.1. India
15.3.1.2. Thailand
15.3.1.3. Indonesia
15.3.1.4. Malaysia
15.3.1.5. Rest of South Asia
15.3.2. By Dosage Form
15.3.3. By Indication
15.3.4. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Dosage Form
15.4.3. By Indication
15.4.4. By End User
15.5. Key Market Participants - Intensity Mapping
15.6. Country-Level Analysis & Forecast
15.6.1. India Drug Formulation Market
15.6.1.1. Introduction
15.6.1.2. Market Analysis and Forecast By Market Taxonomy
15.6.1.2.1. By Dosage Form
15.6.1.2.2. By Indication
15.6.1.2.3. By End User
15.6.2. Thailand Drug Formulation Market
15.6.2.1. Introduction
15.6.2.2. Market Analysis and Forecast By Market Taxonomy
15.6.2.2.1. By Dosage Form
15.6.2.2.2. By Indication
15.6.2.2.3. By End User
15.6.3. Indonesia Drug Formulation Market
15.6.3.1. Introduction
15.6.3.2. Market Analysis and Forecast By Market Taxonomy
15.6.3.2.1. By Dosage Form
15.6.3.2.2. By Indication
15.6.3.2.3. By End User
15.6.4. Malaysia Drug Formulation Market
15.6.4.1. Introduction
15.6.4.2. Market Analysis and Forecast By Market Taxonomy
15.6.4.2.1. By Dosage Form
15.6.4.2.2. By Indication
15.6.4.2.3. By End User
16. East Asia Drug Formulation Market Analysis 2012 to 2021 and Forecast 2022 to 2032
16.1. Introduction
16.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021
16.3. Market Size (US$ Million) By Market Taxonomy, 2022 to 2032
16.3.1. By Country
16.3.1.1. China
16.3.1.2. Japan
16.3.1.3. South Korea
16.3.2. By Dosage Form
16.3.3. By Indication
16.3.4. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Dosage Form
16.4.3. By Indication
16.4.4. By End User
16.5. Key Market Participants - Intensity Mapping
16.6. Country-Level Analysis & Forecast
16.6.1. China Drug Formulation Market
16.6.1.1. Introduction
16.6.1.2. Market Analysis and Forecast By Market Taxonomy
16.6.1.2.1. By Dosage Form
16.6.1.2.2. By Indication
16.6.1.2.3. By End User
16.6.2. Japan Drug Formulation Market
16.6.2.1. Introduction
16.6.2.2. Market Analysis and Forecast By Market Taxonomy
16.6.2.2.1. By Dosage Form
16.6.2.2.2. By Indication
16.6.2.2.3. By End User
16.6.3. South Korea Drug Formulation Market
16.6.3.1. Introduction
16.6.3.2. Market Analysis and Forecast By Market Taxonomy
16.6.3.2.1. By Dosage Form
16.6.3.2.2. By Indication
16.6.3.2.3. By End User
17. Oceania Drug Formulation Market Analysis 2012 to 2021 and Forecast 2022 to 2032
17.1. Introduction
17.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021
17.3. Market Size (US$ Million) By Market Taxonomy, 2022 to 2032
17.3.1. By Country
17.3.1.1. Australia
17.3.1.2. New Zealand
17.3.2. B By Dosage Form
17.3.3. By Indication
17.3.4. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Dosage Form
17.4.3. By Indication
17.4.4. By End User
17.5. Country-Level Analysis & Forecast
17.5.1. Australia Drug Formulation Market
17.5.1.1. Introduction
17.5.1.2. Market Analysis and Forecast By Market Taxonomy
17.5.1.2.1. By Dosage Form
17.5.1.2.2. By Indication
17.5.1.2.3. By End User
17.5.2. New Zealand Drug Formulation Market
17.5.2.1. Introduction
17.5.2.2. Market Analysis and Forecast By Market Taxonomy
17.5.2.2.1. By Dosage Form
17.5.2.2.2. By Indication
17.5.2.2.3. By End User
18. Middle East and Africa Drug Formulation Market Analysis 2012 to 2021and Forecast 2022 to 2032
18.1. Introduction
18.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021
18.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
18.3.1. By Country
18.3.1.1. GCC Countries
18.3.1.2. Turkey
18.3.1.3. Israel
18.3.1.4. South Africa
18.3.1.5. North Africa
18.3.1.6. Rest of Middle East and Africa
18.3.2. By Dosage Form
18.3.3. By Indication
18.3.4. By End User
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Dosage Form
18.4.3. By Indication
18.4.4. By End User
18.5. Key Market Participants - Intensity Mapping
18.6. Country-Level Analysis & Forecast
18.6.1. GCC Countries Drug Formulation Market
18.6.1.1. Introduction
18.6.1.2. Market Analysis and Forecast By Market Taxonomy
18.6.1.2.1. By Dosage Form
18.6.1.2.2. By Indication
18.6.1.2.3. By End User
18.6.2. Turkey Drug Formulation Market
18.6.2.1. Introduction
18.6.2.2. Market Analysis and Forecast By Market Taxonomy
18.6.2.2.1. By Dosage Form
18.6.2.2.2. By Indication
18.6.2.2.3. By End User
18.6.3. Egypt Drug Formulation Market
18.6.3.1. Introduction
18.6.3.2. Market Analysis and Forecast By Market Taxonomy
18.6.3.2.1. By Dosage Form
18.6.3.2.2. By Indication
18.6.3.2.3. By End User
18.6.4. South Africa Drug Formulation Market
18.6.4.1. Introduction
18.6.4.2. Market Analysis and Forecast By Market Taxonomy
18.6.4.2.1. By Dosage Form
18.6.4.2.2. By Indication
18.6.4.2.3. By End User
18.6.5. North Africa Drug Formulation Market
18.6.5.1. Introduction
18.6.5.2. Market Analysis and Forecast By Market Taxonomy
18.6.5.2.1. By Dosage Form
18.6.5.2.2. By Indication
18.6.5.2.3. By End User
19. Market Structure Analysis
19.1. Market Analysis By Tier of Companies
19.2. Market Share Analysis of Top Players
19.3. Market Presence Analysis
20. Competition Analysis
20.1. Competition Dashboard
20.2. Competition Deep Dive
20.2.1. AstraZeneca plc.
20.2.1.1. Overview
20.2.1.2. Product Portfolio
20.2.1.3. SWOT Analysis
20.2.1.4. Strategy Overview
20.2.1.4.1. Marketing Strategies
20.2.1.4.2. Product Strategies
20.2.1.4.3. Channel Strategies
20.2.2. Bristol-Myers Squibb
20.2.2.1. Overview
20.2.2.2. Product Portfolio
20.2.2.3. SWOT Analysis
20.2.2.4. Strategy Overview
20.2.2.4.1. Marketing Strategies
20.2.2.4.2. Product Strategies
20.2.2.4.3. Channel Strategies
20.2.3. Eli Lilly and Company
20.2.3.1. Overview
20.2.3.2. Product Portfolio
20.2.3.3. SWOT Analysis
20.2.3.4. Strategy Overview
20.2.3.4.1. Marketing Strategies
20.2.3.4.2. Product Strategies
20.2.3.4.3. Channel Strategies
20.2.4. Gilead Sciences, Inc.
20.2.4.1. Overview
20.2.4.2. Product Portfolio
20.2.4.3. SWOT Analysis
20.2.4.4. Strategy Overview
20.2.4.4.1. Marketing Strategies
20.2.4.4.2. Product Strategies
20.2.4.4.3. Channel Strategies
20.2.5. Merck & Co., Inc.
20.2.5.1. Overview
20.2.5.2. Product Portfolio
20.2.5.3. SWOT Analysis
20.2.5.4. Strategy Overview
20.2.5.4.1. Marketing Strategies
20.2.5.4.2. Product Strategies
20.2.5.4.3. Channel Strategies
20.2.6. Novartis AG
20.2.6.1. Overview
20.2.6.2. Product Portfolio
20.2.6.3. SWOT Analysis
20.2.6.4. Strategy Overview
20.2.6.4.1. Marketing Strategies
20.2.6.4.2. Product Strategies
20.2.6.4.3. Channel Strategies
20.2.7. Pfizer Inc.
20.2.7.1. Overview
20.2.7.2. Product Portfolio
20.2.7.3. SWOT Analysis
20.2.7.4. Strategy Overview
20.2.7.4.1. Marketing Strategies
20.2.7.4.2. Product Strategies
20.2.7.4.3. Channel Strategies
20.2.8. AbbVie Inc.
20.2.8.1. Overview
20.2.8.2. Product Portfolio
20.2.8.3. SWOT Analysis
20.2.8.4. Strategy Overview
20.2.8.4.1. Marketing Strategies
20.2.8.4.2. Product Strategies
20.2.8.4.3. Channel Strategies
20.2.9. Boehringer Ingelheim International GmbH
20.2.9.1. Overview
20.2.9.2. Product Portfolio
20.2.9.3. SWOT Analysis
20.2.9.4. Strategy Overview
20.2.9.4.1. Marketing Strategies
20.2.9.4.2. Product Strategies
20.2.9.4.3. Channel Strategies
20.2.10. F. Hoffmann-La Roche AG
20.2.10.1. Overview
20.2.10.2. Product Portfolio
20.2.10.3. SWOT Analysis
20.2.10.4. Strategy Overview
20.2.10.4.1. Marketing Strategies
20.2.10.4.2. Product Strategies
20.2.10.4.3. Channel Strategies
20.2.11. Johnson & Johnson
20.2.11.1. Overview
20.2.11.2. Product Portfolio
20.2.11.3. SWOT Analysis
20.2.11.4. Strategy Overview
20.2.11.4.1. Marketing Strategies
20.2.11.4.2. Product Strategies
20.2.11.4.3. Channel Strategies
20.2.12. 3M Company
20.2.12.1. Overview
20.2.12.2. Product Portfolio
20.2.12.3. SWOT Analysis
20.2.12.4. Strategy Overview
20.2.12.4.1. Marketing Strategies
20.2.12.4.2. Product Strategies
20.2.12.4.3. Channel Strategies
20.2.13. Bayer AG
20.2.13.1. Overview
20.2.13.2. Product Portfolio
20.2.13.3. SWOT Analysis
20.2.13.4. Strategy Overview
20.2.13.4.1. Marketing Strategies
20.2.13.4.2. Product Strategies
20.2.13.4.3. Channel Strategies
20.2.14. Teva Pharmaceuticals Industries Ltd.
20.2.14.1. Overview
20.2.14.2. Product Portfolio
20.2.14.3. SWOT Analysis
20.2.14.4. Strategy Overview
20.2.14.4.1. Marketing Strategies
20.2.14.4.2. Product Strategies
20.2.14.4.3. Channel Strategies
20.2.15. Amgen, Inc.
20.2.15.1. Overview
20.2.15.2. Product Portfolio
20.2.15.3. SWOT Analysis
20.2.15.4. Strategy Overview
20.2.15.4.1. Marketing Strategies
20.2.15.4.2. Product Strategies
20.2.15.4.3. Channel Strategies
20.2.16. Sanofi SA
20.2.16.1. Overview
20.2.16.2. Product Portfolio
20.2.16.3. SWOT Analysis
20.2.16.4. Strategy Overview
20.2.16.4.1. Marketing Strategies
20.2.16.4.2. Product Strategies
20.2.16.4.3. Channel Strategies
20.2.17. GlaxoSmithKline plc
20.2.17.1. Overview
20.2.17.2. Product Portfolio
20.2.17.3. SWOT Analysis
20.2.17.4. Strategy Overview
20.2.17.4.1. Marketing Strategies
20.2.17.4.2. Product Strategies
20.2.17.4.3. Channel Strategies
20.2.18. Boston Scientific Corporation
20.2.18.1. Overview
20.2.18.2. Product Portfolio
20.2.18.3. SWOT Analysis
20.2.18.4. Strategy Overview
20.2.18.4.1. Marketing Strategies
20.2.18.4.2. Product Strategies
20.2.18.4.3. Channel Strategies
20.2.19. Gerresheimer AG
20.2.19.1. Overview
20.2.19.2. Product Portfolio
20.2.19.3. SWOT Analysis
20.2.19.4. Strategy Overview
20.2.19.4.1. Marketing Strategies
20.2.19.4.2. Product Strategies
20.2.19.4.3. Channel Strategies
20.2.20. Nimbus Therapeutics
20.2.20.1. Overview
20.2.20.2. Product Portfolio
20.2.20.3. SWOT Analysis
20.2.20.4. Strategy Overview
20.2.20.4.1. Marketing Strategies
20.2.20.4.2. Product Strategies
20.2.20.4.3. Channel Strategies
20.2.21. Antares Pharma, Inc.
20.2.21.1. Overview
20.2.21.2. Product Portfolio
20.2.21.3. SWOT Analysis
20.2.21.4. Strategy Overview
20.2.21.4.1. Marketing Strategies
20.2.21.4.2. Product Strategies
20.2.21.4.3. Channel Strategies
20.2.22. IDEAYA Biosciences, Inc.
20.2.22.1. Overview
20.2.22.2. Product Portfolio
20.2.22.3. SWOT Analysis
20.2.22.4. Strategy Overview
20.2.22.4.1. Marketing Strategies
20.2.22.4.2. Product Strategies
20.2.22.4.3. Channel Strategies
21. Assumptions and Acronyms Used22. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 01: Global Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 02: Global Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 03: Global Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 04: Global Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 05: Global Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Indication
Table 06: Global Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Indication
Table 07: Global Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User
Table 08: Global Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User
Table 09: Global Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Region
Table 10: Global Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Region
Table 11: North America Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country
Table 12: North America Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country
Table 13: North America Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 14: North America Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 15: North America Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 16: North America Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 17: North America Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Indication
Table 18: North America Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Indication
Table 19: Global Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User
Table 20: Global Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User
Table 20 :Latin America Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User
Table 21: Latin America Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country
Table 22: Latin America Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country
Table 23: Latin America Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 24: Latin America Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 25: Latin America Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 26: Latin America Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 27: Latin America Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Indication
Table 28: Latin America Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Indication
Table 30 :Latin America Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User
Table 31 : Europe Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country
Table 32 : Europe Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country
Table 33 : Europe Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 34: Europe Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 35: Europe Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 36 : Europe Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 37: Europe Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Indication
Table 38 : Europe Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Indication
Table 39 : Europe Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User
Table 40 : Europe Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User
Table 41 : South Asia Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country
Table 42 : South Asia Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country
Table 43: South Asia Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 44 :South Asia Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 45 :South Asia Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 46 :South Asia Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 47 :South Asia Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Indication
Table 48 : South Asia Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Indication
Table 49 : South Asia Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User
Table 50 : South Asia Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User
Table 51: East Asia Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country
Table 52: East Asia Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country
Table 53 :East Asia Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 54: East Asia Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 55: East Asia Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 56: East Asia Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 57: East Asia Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Indication
Table 58: East Asia Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Indication
Table 59: East Asia Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User
Table 60: East Asia Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User
Table 61: Oceania Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country
Table 62: Oceania Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country
Table 63 :Oceania Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 64 :Oceania Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 65: Oceania Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 66: Oceania Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 67 : Oceania Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Indication
Table 68 : Oceania Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Indication
Table 69: Oceania Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User
Table 70: Oceania Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User
Table 71 : Middle East & Africa Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country
Table 72 : Middle East & Africa Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country
Table 73 :Middle East & Africa Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 74 :Middle East & Africa Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 75 : Middle East & Africa Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 76 : Middle East & Africa Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
Table 77: Middle East & Africa Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Indication
Table 78: Middle East & Africa Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Indication
Table 79: Middle East & Africa Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User
Table 80: Middle East & Africa Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 01: Global Drug Formulation Market Size (US$ Mn) 2021A & 2032F
Figure 02: Global Drug Formulation Market Share 2021A, By Dosage Form
Figure 03: Global Drug Formulation Market Share 2021A, By Indication
Figure 04: Global Drug Formulation Market Share 2021A, By End User
Figure 05: Global Drug Formulation Market Share 2021A, By Region
Figure 06: Global Drug Formulation Market Size (US$ Bn) Analysis, 2012 to 2021
Figure 07: Global Drug Formulation Market Size (US$ Bn) & Y-o-Y Growth (%) Analysis, 2022 to 2032
Figure 08: Global Drug Formulation Market Absolute $ Opportunity Analysis, 2022 to 2032
Figure 09: Global Drug Formulation Market Analysis By Dosage Form 2022 to 2032
Figure 10: Global Drug Formulation Market Y-o-Y Growth Projections By Dosage Form, 2022 to 2032
Figure 11: Global Drug Formulation Market Attractiveness, By Dosage Form, 2022 to 2032
Figure 12: Global Drug Formulation Market Analysis By Indication 2021 to 2032
Figure 13: Global Drug Formulation Market Y-o-Y Growth Projections By Indication, 2022 to 2032
Figure 14: Global Drug Formulation Market Attractiveness, By Indication, 2022 to 2032
Figure 15: Global Drug Formulation Market Analysis By End User, 2021 to 2032
Figure 16: Global Drug Formulation Market Y-o-Y Growth Projections By End User, 2022 to 2032
Figure 17: Global Drug Formulation Market Attractiveness, By End User, 2022 to 2032
Figure 18: Global Drug Formulation Market Analysis By Region, 2021 to 2032
Figure 19: Global Drug Formulation Market Y-o-Y Growth Projections By Region, 2022 to 2032
Figure 20: Global Drug Formulation Market Attractiveness, By Region, 2022 to 2032
Figure 21: North America Drug Formulation Market Value Share, By Dosage Form 2022 (E)
Figure 22: North America Drug Formulation Market Value Share, By Indication 2022 (E)
Figure 23: North America Drug Formulation Market Value Share, By End User 2022 (E)
Figure 24: North America Drug Formulation Market Value Share, By Region 2022 (E)
Figure 25: North America Drug Formulation Market Size (US$ Bn) Analysis, 2012 to 2021
Figure 26: North America Drug Formulation Market Size (US$ Bn) & Y-o-Y Growth (%) Analysis, 2022 to 2032
Figure 27: North America Drug Formulation Market Attractiveness Analysis, By Country
Figure 28: North America Drug Formulation Market Attractiveness Analysis, By Dosage Form
Figure 29: North America Drug Formulation Market Attractiveness, By Indication
Figure 30: North America Drug Formulation Market Attractiveness, By End User
Figure 31: US Market Value Proportion Analysis, 2021
Figure 32: Global Vs. US Growth Comparison, 2021 to 2032
Figure 33: US Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032
Figure 34: US Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032
Figure 35: US Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032
Figure 36: Canada Market Value Proportion Analysis, 2021
Figure 37: Global Vs. Canada Growth Comparison, 2021 to 2032
Figure 38: Canada Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032
Figure 39: Canada Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032
Figure 40: Canada Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032
Figure 41: Latin America Drug Formulation Market Value Share, By Dosage Form 2022 (E)
Figure 42: Latin America Drug Formulation Market Value Share, By Indication 2022 (E)
Figure 43: Latin America Drug Formulation Market Value Share, By End User 2022 (E)
Figure 44: Latin America Drug Formulation Market Value Share, By Region 2022 (E)
Figure 45: Latin America Drug Formulation Market Size (US$ Bn) Analysis, 2012 to 2021
Figure 46: Latin America Drug Formulation Market Size (US$ Bn) & Y-o-Y Growth (%) Analysis, 2022 to 2032
Figure 47: Latin America Drug Formulation Market Attractiveness Analysis, By Country
Figure 48: Latin America Drug Formulation Market Attractiveness Analysis, By Dosage Form
Figure 49: Latin America Drug Formulation Market Attractiveness, By Indication
Figure 50: Latin America Drug Formulation Market Attractiveness, By End User
Figure 51: Brazil Market Value Proportion Analysis, 2021
Figure 52: Global Vs. Brazil Growth Comparison, 2021 to 2032
Figure 53: Brazil Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032
Figure 54: Brazil Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032
Figure 55: Brazil Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032
Figure 56: Mexico Market Value Proportion Analysis, 2021
Figure 57: Global Vs. Mexico Growth Comparison, 2021 to 2032
Figure 58: Mexico Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032
Figure 59: Mexico Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032
Figure 60: Mexico Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032
Figure 61: Argentina Market Value Proportion Analysis, 2021
Figure 62: Global Vs. Argentina Growth Comparison, 2021 to 2032
Figure 63: Argentina Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032
Figure 64: Argentina Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032
Figure 65: Argentina Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032
Figure 66: Europe Drug Formulation Market Value Share, By Dosage Form 2022 (E)
Figure 67: Europe Drug Formulation Market Value Share, By Indication 2022 (E)
Figure 68: Europe Drug Formulation Market Value Share, By End User 2022 (E)
Figure 69: Europe Drug Formulation Market Value Share, By Region 2022 (E)
Figure 70: Europe Drug Formulation Market Size (US$ Bn) Analysis, 2012 to 2021
Figure 71: Europe Drug Formulation Market Size (US$ Bn) & Y-o-Y Growth (%) Analysis, 2022 to 2032
Figure 72: Europe Drug Formulation Market Attractiveness Analysis, By Country
Figure 73: Europe Drug Formulation Market Attractiveness Analysis, By Dosage Form
Figure 74: Europe Drug Formulation Market Attractiveness, By Indication
Figure 75: Europe Drug Formulation Market Attractiveness, By End User
Figure 76: UK Market Value Proportion Analysis, 2021
Figure 77: Global Vs. UK Growth Comparison, 2021 to 2032
Figure 78: UK Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032
Figure 79: UK Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032
Figure 80: UK Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032
Figure 81: Germany Market Value Proportion Analysis, 2021
Figure 82: Global Vs. Germany Growth Comparison, 2021 to 2032
Figure 83: Germany Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032
Figure 84: Germany Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032
Figure 85: Germany Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032
Figure 86: Italy Market Value Proportion Analysis, 2021
Figure 87: Global Vs. Italy Growth Comparison, 2021 to 2032
Figure 88: Italy Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032
Figure 89: Italy Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032
Figure 90: Italy Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032
Figure 91: France Market Value Proportion Analysis, 2021
Figure 92: Global Vs. France Growth Comparison, 2021 to 2032
Figure 93: France Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032
Figure 94: France Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032
Figure 95: France Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032
Figure 96: Spain Market Value Proportion Analysis, 2021
Figure 97: Global Vs. Spain Growth Comparison, 2021 to 2032
Figure 98: Spain Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032
Figure 99: Spain Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032
Figure 100: Spain Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032
Figure 101: BENELUX Market Value Proportion Analysis, 2021
Figure 102: Global Vs. BENELUX Growth Comparison, 2021 to 2032
Figure 103: BENELUX Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032
Figure 104: BENELUX Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032
Figure 105: BENELUX Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032
Figure 106: Russia Market Value Proportion Analysis, 2021
Figure 107: Global Vs. Russia Growth Comparison, 2021 to 2032
Figure 108: Russia Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032
Figure 109: Russia Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032
Figure 110: Russia Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032
Figure 111: South Asia Drug Formulation Market Value Share, By Dosage Form 2022 (E)
Figure 112: South Asia Drug Formulation Market Value Share, By Indication 2022 (E)
Figure 113: South Asia Drug Formulation Market Value Share, By End User 2022 (E)
Figure 114: South Asia Drug Formulation Market Value Share, By Region 2022 (E)
Figure 115: South Asia Drug Formulation Market Size (US$ Bn) Analysis, 2012 to 2021
Figure 116: South Asia Drug Formulation Market Size (US$ Bn) & Y-o-Y Growth (%) Analysis, 2022 to 2032
Figure 117: South Asia Drug Formulation Market Attractiveness Analysis, By Country
Figure 118: South Asia Drug Formulation Market Attractiveness Analysis, By Dosage Form
Figure 119: South Asia Drug Formulation Market Attractiveness, By Indication
Figure 120: South Asia Drug Formulation Market Attractiveness, By End User
Figure 121: India Market Value Proportion Analysis, 2021
Figure 122: Global Vs. India Growth Comparison, 2021 to 2032
Figure 123: India Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032
Figure 124: India Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032
Figure 125: India Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032
Figure 126: Malaysia Market Value Proportion Analysis, 2021
Figure 127: Global Vs. Malaysia Growth Comparison, 2021 to 2032
Figure 128: Malaysia Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032
Figure 129: Malaysia Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032
Figure 130: Malaysia Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032
Figure 131: Thailand Market Value Proportion Analysis, 2021
Figure 132: Global Vs. Thailand Growth Comparison, 2021 to 2032
Figure 133: Thailand Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032
Figure 134: Thailand Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032
Figure 135: Thailand Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032
Figure 136: Indonesia Market Value Proportion Analysis, 2021
Figure 137: Global Vs. Indonesia Growth Comparison, 2021 to 2032
Figure 138: Indonesia Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032
Figure 139: Indonesia Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032
Figure 140: Indonesia Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032
Figure 141: East Asia Drug Formulation Market Value Share, By Dosage Form 2022 (E)
Figure 142: East Asia Drug Formulation Market Value Share, By Indication 2022 (E)
Figure 143: East Asia Drug Formulation Market Value Share, By End User 2022 (E)
Figure 144: East Asia Drug Formulation Market Value Share, By Region 2022 (E)
Figure 145: East Asia Drug Formulation Market Size (US$ Bn) Analysis, 2012 to 2021
Figure 146: East Asia Drug Formulation Market Size (US$ Bn) & Y-o-Y Growth (%) Analysis, 2022 to 2032
Figure 147: East Asia Drug Formulation Market Attractiveness Analysis, By Country
Figure 148: East Asia Drug Formulation Market Attractiveness Analysis, By Dosage Form
Figure 149: East Asia Drug Formulation Market Attractiveness, By Indication
Figure 150: East Asia Drug Formulation Market Attractiveness, By End User
Figure 151: China Market Value Proportion Analysis, 2021
Figure 152: Global Vs. China Growth Comparison, 2021 to 2032
Figure 153: China Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032
Figure 154: China Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032
Figure 155: China Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032
Figure 156: Japan Market Value Proportion Analysis, 2021
Figure 157: Global Vs. Japan Growth Comparison, 2021 to 2032
Figure 158: Japan Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032
Figure 159: Japan Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032
Figure 160: Japan Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032
Figure 161: South Korea Market Value Proportion Analysis, 2021
Figure 162: Global Vs. South Korea Growth Comparison, 2021 to 2032
Figure 163: South Korea Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032
Figure 164: South Korea Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032
Figure 165: South Korea Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032
Figure 166: Oceania Drug Formulation Market Value Share, By Dosage Form 2022 (E)
Figure 167: Oceania Drug Formulation Market Value Share, By Indication 2022 (E)
Figure 168: Oceania Drug Formulation Market Value Share, By End User 2022 (E)
Figure 169: Oceania Drug Formulation Market Value Share, By Region 2022 (E)
Figure 170: Oceania Drug Formulation Market Size (US$ Bn) Analysis, 2012 to 2021
Figure 171: Oceania Drug Formulation Market Size (US$ Bn) & Y-o-Y Growth (%) Analysis, 2022 to 2032
Figure 172: Oceania Drug Formulation Market Attractiveness Analysis, By Country
Figure 173: Oceania Drug Formulation Market Attractiveness Analysis, By Dosage Form
Figure 174: Oceania Drug Formulation Market Attractiveness, By Indication
Figure 175: Oceania Drug Formulation Market Attractiveness, By End User
Figure 176: Australia Market Value Proportion Analysis, 2021
Figure 177: Global Vs. Australia Growth Comparison, 2021 to 2032
Figure 178: Australia Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032
Figure 179: Australia Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032
Figure 180: Australia Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032
Figure 181: New Zealand Market Value Proportion Analysis, 2021
Figure 182: Global Vs. New Zealand Growth Comparison, 2021 to 2032
Figure 183: New Zealand Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032
Figure 184: New Zealand Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032
Figure 185: New Zealand Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032
Figure 186: Middle East & Africa Drug Formulation Market Value Share, By Dosage Form 2022 (E)
Figure 187: Middle East & Africa Drug Formulation Market Value Share, By Indication 2022 (E)
Figure 188: Middle East & Africa Drug Formulation Market Value Share, By End User 2022 (E)
Figure 189: Middle East & Africa Drug Formulation Market Value Share, By Region 2022 (E)
Figure 190: Middle East & Africa Drug Formulation Market Size (US$ Bn) Analysis, 2012 to 2021
Figure 191: Middle East & Africa Drug Formulation Market Size (US$ Bn) & Y-o-Y Growth (%) Analysis, 2022 to 2032
Figure 192: Middle East & Africa Drug Formulation Market Attractiveness Analysis, By Country
Figure 193: Middle East & Africa Drug Formulation Market Attractiveness Analysis, By Dosage Form
Figure 194: Middle East & Africa Drug Formulation Market Attractiveness, By Indication
Figure 195: Middle East & Africa Drug Formulation Market Attractiveness, By End User
Figure 196: GCC Countries Market Value Proportion Analysis, 2021
Figure 197: Global Vs. GCC Countries Growth Comparison, 2021 to 2032
Figure 198: GCC Countries Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032
Figure 199: GCC Countries Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032
Figure 200: GCC Countries Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032
Figure 201: Turkey Market Value Proportion Analysis, 2021
Figure 202: Global Vs. Turkey Growth Comparison, 2021 to 2032
Figure 203: Turkey Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032
Figure 204: Turkey Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032
Figure 205: Turkey Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032
Figure 206: Egypt Market Value Proportion Analysis, 2021
Figure 207: Global Vs. Egypt Growth Comparison, 2021 to 2032
Figure 208: Egypt Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032
Figure 209: Egypt Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032
Figure 210: Egypt Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032
Figure 211: South Africa Market Value Proportion Analysis, 2021
Figure 212: Global Vs. South Africa Growth Comparison, 2021 to 2032
Figure 213: South Africa Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032
Figure 214: South Africa Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032
Figure 215: South Africa Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032
Figure 216: North Africa Market Value Proportion Analysis, 2021
Figure 217: Global Vs. North Africa Growth Comparison, 2021 to 2032
Figure 218: North Africa Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032
Figure 219: North Africa Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032
Figure 220: North Africa Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032
